Treatment of candidaemia in a nationwide setting; increased survival with primary echinocandin treatment

References

• Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000;30(4):662–678.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):409–417.
   PubMedGoogle Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–535.
   PubMed Web of Science ®Google Scholar
• Behandlingsvejledning inklusiv laegemiddelrekommandation for systemisk antimykotisk behandling; 2016. Available from: http://www.regioner.dk/media/3739/beh-og-rek-antimykotika-vers-2-0-okt-2016.pdf. Accessed June 27, 2017.
   Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19–37.
   PubMed Web of Science ®Google Scholar
• Bow EJ, Evans G, Fuller J, et al. Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol. 2010;21(4):e122–e150.
   PubMed Web of Science ®Google Scholar
• Ruhnke M, Rickerts V, Cornely OA, et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses. 2011;54(4):279–310.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Dzajic E, Jensen RH, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect. 2013;19(8):e343–e353.
   PubMedGoogle Scholar
• Astvad KMT, Johansen HK, Røder BL, et al. Update from a 12-year nationwide fungemia surveillance: increasing intrinsic and acquired resistance causes concern. J Clin Microbiol. 2017;56(4):pii:e01564-17.
   Web of Science ®Google Scholar
• Reboli AC, Shorr AF, Rotstein C, et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis. 2011;11:261.
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472–2482.
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331(20):1325–1330.
   PubMed Web of Science ®Google Scholar
• Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54(8):1110–1122.
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366(9495):1435–1442.
   PubMed Web of Science ®Google Scholar
• Puig-Asensio M, Fernández-Ruiz M, Aguado JM, et al. Propensity score analysis of the role of initial antifungal therapy in the outcome of Candida glabrata bloodstream infections. Antimicrob Agents Chemother. 2016;60(6):3291–3300.
   PubMed Web of Science ®Google Scholar
• Murri R, Scoppettuolo G, Ventura G, et al. Initial antifungal strategy does not correlate with mortality in patients with candidemia. Eur J Clin Microbiol Infect Dis. 2016;35(2):187–193.
   PubMed Web of Science ®Google Scholar
• de Rosa FG, Corcione S, Filippini C, et al. The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected]. PLoS ONE. 2015;10(5):e0125149.
   PubMed Web of Science ®Google Scholar
• Luzzati R, Merelli M, Ansaldi F, et al. Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study. Infection. 2016;44(6):747–755.
   PubMed Web of Science ®Google Scholar
• Leroy O, Bailly S, Gangneux JP, et al. Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. Ann Intensive Care. 2016;6(1):2.
   PubMedGoogle Scholar
• Arendrup MC, Bruun B, Christensen JJ, et al. National surveillance of fungemia in Denmark (2004 to 2009. J Clin Microbiol. 2011;49(1):325–334.
   PubMed Web of Science ®Google Scholar
• EUCAST. EUCAST breakpoints and ECOFF. Available from: http://www.eucast.org/clinical_breakpoints/. Accessed May 09, 2018.
   Google Scholar
• Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008. Diagn Microbiol Infect Dis. 2012;74(4):323–331.
   PubMed Web of Science ®Google Scholar
• Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis. 2012;55(10):1352–1361.
   PubMed Web of Science ®Google Scholar
• Puig-Asensio M, Ruiz-Camps I, Fernández-Ruiz M, et al. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. Clin Microbiol Infect. 2015;21(5):491.e1–491.e10.
   Web of Science ®Google Scholar
• Almirante B, Rodríguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2005;43(4):1829–1835.
   PubMed Web of Science ®Google Scholar
• Hirano R, Sakamoto Y, Kitazawa J, Yamamoto S, Kayaba H. Epidemiology, practice patterns, and prognostic factors for candidemia; and characteristics of fourteen patients with breakthrough Candida bloodstream infections: a single tertiary hospital experience in Japan. Infect Drug Resist. 2018;11:821–833.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55(2):532–538.
   PubMed Web of Science ®Google Scholar
• Puig-Asensio M, Pemán J, Zaragoza R, et al. Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med. 2014;42(6):1423–1432.
   PubMed Web of Science ®Google Scholar
• Blanchard E, Lortholary O, Boukris-Sitbon K, et al. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother. 2011;55(11):5358–5361.
   PubMed Web of Science ®Google Scholar
• Mann PA, Mcnicholas PM, Chau AS, et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother. 2009;53(12):5026–5034.
   PubMed Web of Science ®Google Scholar
• Jensen RH, Johansen HK, Søes LM, et al. Posttreatment antifungal resistance among colonizing Candida isolates in candidemia patients: results from a systematic multicenter study. Antimicrob Agents Chemother. 2016;60(3):1500–1508.
   Web of Science ®Google Scholar
• Puig-Asensio M, Padilla B, Garnacho-Montero J, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect. 2014;20(4):O245–O254.
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Orsetti E, Gesuita R, Skrami E, Manso E; Candidemia Study Group. Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014. Infection. 2016;44(2):205–213.
   PubMed Web of Science ®Google Scholar
• Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1(11):710–719.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.
   PubMed Web of Science ®Google Scholar
• Trouvé C, Blot S, Hayette MP, et al. Epidemiology and reporting of candidaemia in Belgium: a multi-centre study. Eur J Clin Microbiol Infect Dis. 2017;36(4):649–655.
   PubMed Web of Science ®Google Scholar
• Rajendran R, Sherry L, Deshpande A, et al. A prospective surveillance study of candidaemia: epidemiology, risk factors, antifungal treatment and outcome in hospitalized patients. Front Microbiol. 2016; 7:915.
   PubMed Web of Science ®Google Scholar
• Hesstvedt L, Arendrup MC, Poikonen E, et al. Differences in epidemiology of candidaemia in the Nordic countries - what is to blame? Mycoses. 2017;60(1):11–19.
   PubMed Web of Science ®Google Scholar
• Ericsson J, Chryssanthou E, Klingspor L, et al. Candidaemia in Sweden: a nationwide prospective observational survey. Clin Microbiol Infect. 2013;19(4):E218–E221.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Sulim S, Holm A, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol. 2011;49(9):3300–3308.
   PubMed Web of Science ®Google Scholar
• López-Cortés LE, Almirante B, Cuenca-Estrella M, et al. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. Clin Microbiol Infect. 2016;22(8):733.e1–73733.
   Web of Science ®Google Scholar